Largest opioid review finds limited effectiveness for most acute pain conditions
A comprehensive review of 59 systematic reviews by University of Sydney researchers found that opioid medications provide only limited, short-term relief for most acute pain conditions and often perform no better than placebo. The analysis examined evidence across more than 50 acute pain conditions and found opioids showed modest benefits only for specific conditions like dental surgery pain and childbirth, while showing no advantage for kidney stones, some limb surgeries, and other common conditions. The findings challenge widespread prescribing practices and highlight safety concerns including nausea, vomiting, and risks of dependence that can develop within days of first use.
Researchers from the University of Sydney conducted the largest review to date of opioid effectiveness, analyzing evidence from 59 systematic reviews covering more than 50 acute pain conditions in both children and adults. The study, published in the journal Drugs, found that oral opioids provided only slightly better pain relief than placebo for most acute pain conditions, with benefits typically lasting only a few hours. Opioids showed modest short-term benefits for specific conditions including stomach pain, dental surgery pain, ear procedures, traumatic limb injuries, childbirth, and bunion removal, but demonstrated no advantage over placebo for kidney stone pain, certain limb surgeries, tonsil removal pain, and newborn pain. Beyond limited effectiveness, the review identified significant safety concerns: opioids increased the risk of side effects such as nausea and vomiting in several situations, and the researchers noted that dependence can develop quickly, sometimes within days of first use. The authors emphasized that many clinical trials failed to adequately report side effects, suggesting actual risks may be underestimated, and called for more judicious prescribing practices and better patient informed consent.
What's missing
The study's own limitations include reliance on published trial data (which may not reflect real-world prescribing patterns), the fact that some trials evaluated only single doses rather than repeated use, and acknowledged gaps in safety reporting across many clinical trials. The review does not address chronic pain conditions, focusing exclusively on acute pain.
What different sources said
- Science DailyCenter
World's largest opioid review finds they often don't work
Related
Person dies from rare Murray Valley Encephalitis virus in Western Australia
A person has died after contracting Murray Valley Encephalitis, a rare mosquito-borne virus, while travelling in Western Australia's north, marking the first reported death from the virus in WA this year. The individual was likely exposed in early May in the West Kimberley region, about 2,000 kilometres north of Perth, before being transferred to a Perth hospital where they died. Health authorities are urging residents and tourists to protect themselves from mosquito bites as the region enters its peak tourism season, noting the virus can cause serious brain infection though complications remain rare.
Shigellosis outbreak in Wayanad rises to three confirmed cases; health officials launch investigation
A third student tested positive for shigellosis in Wayanad, Kerala, following an outbreak at Mar Baselios AUP School, bringing confirmed cases to three. The bacterial infection has caused symptoms in 473 people total, with 58 currently hospitalized, prompting health officials to investigate the source and implement stricter sanitation measures. The outbreak highlights concerns about water safety and food hygiene in the region, with authorities conducting well chlorination and inspections of food establishments.
Red-Light Therapy for Hair Loss: Clinical Evidence and Consumer Device Reviews
Wired published a 2026 guide reviewing red-light therapy devices for hair restoration, reporting that clinical studies suggest the treatment can increase blood circulation, reduce inflammation, and support hair follicle growth. Red-light therapy has emerged as an at-home alternative to traditional hair-loss treatments like topical remedies or surgical procedures. The guide matters because hair loss affects millions, and if clinically validated, at-home devices could democratize access to a non-invasive treatment option.